ESCRS - FPS09.02 - Clinical Outcomes Of Bilateral Implantation Of A Non-Diffractive Extended-Vision Intraocular Lens (Acrysof Iq Vivity)

Clinical Outcomes Of Bilateral Implantation Of A Non-Diffractive Extended-Vision Intraocular Lens (Acrysof Iq Vivity)

Published 2022 - 40th Congress of the ESCRS

Reference: FPS09.02 | Type: Free paper | DOI: 10.82333/nzfb-y955

Authors: Celso Miguel Furtado Cabral Gomes Costa* 1 , Telmo Cortinhal 1 , Maria Silva 2 , Miguel Raimundo 3 , Maria J. Quadrado 3 , Joaquim N. Murta 3

1Department of Ophthalmology,Centro Hospitalar e Universitário de Coimbra (CHUC),Coimbra,Portugal;Faculty of Medicine,University of Coimbra,Coimbra,Portugal;Clinical Academic Center of Coimbra,CACC,Coimbra,Portugal, 2Unidade de Oftalmologia de Coimbra,UOC,Coimbra,Portugal, 3Department of Ophthalmology,Centro Hospitalar e Universitário de Coimbra (CHUC),Coimbra,Portugal;Faculty of Medicine,University of Coimbra,Coimbra,Portugal;Clinical Academic Center of Coimbra,CACC,Coimbra,Portugal;Unidade de Oftalmologia de Coimbra,UOC,Coimbra,Portugal

Purpose

To report the visual and refractive outcomes and patient-reported outcomes following bilateral sequential cataract surgery with implantation of two lenses: a non-diffractive extended-vision intraocular lens (IOLs): AcrySof IQ Vivity DFT015 and the toric version AcrySof IQ Vivity Toric DFTx15.

Setting

Private practice (Unidade de Oftalmologia de Coimbra, UOC, Coimbra, Portugal)

Methods

Prospective consecutive case series of patients submitted to uncomplicated phacoemulsification with bilateral sequential implantation of AcrySof IQ Vivity DFT015 / AcrySof IQ Vivity Toric DFTx15, targeting minimonovision (nearest power for emmetropia in the dominant eye, between -0.25D and -0.50D in the nondominant eye). Clinical measures, including monocular and binocular uncorrected distance visual acuity (UDVA), binocular corrected distance (CDVA), intermediate 66cm (UIVA), and near 40cm (UNVA) visual acuity and subjective refraction were assessed 1-2 months postoperatively. Spectacle independence, photic phenomena and activity limitations in daily life were evaluated through questionnaires (IOLSAT, QUVID and Catquest-9SF, respectively).

Results

Two-hundred and eight eyes from 104 patients were enrolled, age 64.65±8.84 years old, 67.31% female (70), with 168 eyes implanted with an AcrySof IQ Vivity DFT015 and 40 eyes with an AcrySof IQ Vivity Toric DFTx15. Binocular mean UDVA was 0.03 logMAR (± 0.08), binocular mean UIVA was 0.08 logMAR (± 0.07), binocular mean UNVA was 0.14 logMAR (± 0.11) and mean SE was -0.24D (± 0.42D) (min -0.75D, max +0.25D). Mean residual astigmatism in toric IOL implanted eyes was 0.3D (± 0.48D). The refractive targets for minimonovision for dominant and nondominant eyes were met in 91.34% and 57.69% of cases, respectively. Reported outcomes on vision-related quality of life, spectacle independence and visual disturbances were excellent.

Conclusions

Our work supports that bilateral implantation of this model of non-diffractive extended vision IOL (AcrySof IQ Vivity platform) in a mini monovison strategy provides excellent uncorrected binocular distance and intermediate visual acuities, and even good near visual acuity in photopic conditions. A high level of patient satisfaction and spectacle independence was achieved, with minimal unwanted visual effects, as evaluated by patient-reported outcomes.